Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: A pharmacology-guided schedule

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 3, 2006, Pages 731-737

  Numico, Gianmauro ^a   Russi, Elvio G ^a   Vitiello, Raffele ^b   Sorrentino, Raffaele ^c   Colantonio, Ida ^a   Cipolat, Marco ^a   Taglianti, Riccardo Vigna ^a   Pelissero, Antonio ^a   Fea, Elena ^a   Granetto, Cristina ^a   Di Costanzo, Gianna ^a   Gasco, Milena ^a   Garrone, Ornella ^a   Occelli, Marcella ^a   Merlano, Marco ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b S Annunziata Hospital   (Italy)

^c C Arrigo Children's Hospital   (Italy)

Author keywords

Chemoradiotherapy; gemcitabine; Head and neck cancer

Indexed keywords

BIOMEDICAL ENGINEERING; CHEMOTHERAPY; RADIATION EFFECTS; RADIOTHERAPY; TUMORS;

CELL CARCINOMAS; CHEMORADIOTHERAPY; GEMCITABINE; METASTASES;

PATIENT MONITORING;

ANTINEOPLASTIC AGENT; CISPLATIN; ERYTHROPOIETIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FEVER; EDEMA; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; FISTULA; FOLLOW UP; GLOTTIS EDEMA; HEAD AND NECK CANCER; HUMAN; HYPOMAGNESEMIA; INFECTION COMPLICATION; LARYNX CARCINOMA; MALE; METASTASIS; MOUTH CARCINOMA; MULTIMODALITY CANCER THERAPY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHARYNX CARCINOMA; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RECURRENT CANCER; RISK REDUCTION; SEPSIS; SKIN MANIFESTATION; SOFT TISSUE EDEMA; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPATHY; TONSIL ULCER; ULCER; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PHARYNGEAL NEOPLASMS; STOMATITIS;

EID: 33748949062     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.059     Document Type: Article

References (27)

1. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data. Lancet 355 (2000) 949-955
2. Adelstein D.J., Li Y., Adams G.L., et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head-and-neck cancer. J Clin Oncol 21 (2003) 92-98
3. Huguenin P., Beer K.T., Allal A., et al. Concomitant cisplatin significantly improves locoregional control in advanced head-and-neck cancer treated with hyperfractionated radiotherapy. J Clin Oncol 22 (2004) 4665-4673
4. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced stage oropharynx carcinoma. J Clin Oncol 22 (2004) 69-76
5. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
6. Ang K.K., Harris J., Garden A.S., et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II trial 99-14. J Clin Oncol 23 (2005) 3008-3015
7. Vokes E.E., Stenson K., Rosen F.R., et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head-and-neck cancer. J Clin Oncol 21 (2003) 320-326
8. Merlano M., Benasso M., Corvò R., et al. Five-year update of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88 (1996) 583-589
9. Corvò R., Benasso M., Sanguineti G., et al. Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Cancer 92 (2001) 2856-2867
10. Pauwels B., Korst A.E.C., Lardon F., et al. Combined modality therapy of gemcitabine and radiation. Oncologist 10 (2005) 34-51
11. Shewach D.S., and Lawrence T.S. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 23 Suppl 10 (1996) 65-71
12. Benasso M., Merlano M., Sanguineti G., et al. Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: A feasibility study. Am J Clin Oncol 24 (2001) 618-622
13. Milas L., Fuji T., and Hunter N. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59 (1999) 107-114
14. Mason K.A., Milas L., Hunter N.R., et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 44 (1999) 1125-1135
15. Ang K.K., Kaander J.H.A.M., and Peters L.J. Radiotherapy for head-and-neck cancers (1994), Lea & Febiger, Philadelphia
16. ICRU. Prescribing, recording, and reporting photon beam therapy: ICRU Report 50 (1993), International Commission on Radiation Units and Measurements, Bethesda, MD
17. Ozer H., Armitage J.O., Bennet C.L., et al. 2000 Update of recommendations for the use of hemopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 18 (2000) 3558-3585
18. Benasso M., Corvò R., Ponzanelli A., et al. Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck. Ann Oncol 15 (2004) 646-652
19. Abbruzzese J.L., Grunewald R., Weeks E.A., et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9 (1991) 491-498
20. Lawrence T.S., Eisbruch A., and Shewach D.S. Gemcitabine-mediated radiosensitization. Semin Oncol 24 Suppl 7 (1997) 24-28
21. Milano M.T., Haraf D.J., Stenson K.M., et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res 10 (2004) 4922-4932
22. Eisbruch A., Shewach D.S., Bradford C.R., et al. Radiation concurrent with gemcitabine for locally advanced head-and-neck cancer: A phase I trial and intracellular drug incorporation study. J Clin Oncol 19 (2001) 792-799
23. Aguilar-Ponce J.L., Granados-Garcìa M., Villavicencio V., et al. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 15 (2004) 301-306
24. Marik P.E., and Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest 124 (2003) 328-336
25. Eisbruch A., Lyden T., Bradford C.R., et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 53 (2002) 23-28
26. Joerger M., Gunz A., Speich R., et al. Gemcitabine-related pulmonary toxicity. Swiss Med Wkly 132 (2002) 17-20
27. Milano M.T., Vokes E.E., Salama J.K., et al. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1096-1106